Database : MEDLINE
Search on : Keratoacanthoma [Words]
References found : 1949 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 195 go to page                         

  1 / 1949 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29369392
[Au] Autor:Kailas A; Elston DM; Crater SE; Cerruto CA
[Ad] Address:University of Central Florida College of Medicine, Orlando, Florida.
[Ti] Title:Cutaneous intravascular CD30+ T-cell pseudolymphoma occurring in a regressing keratoacanthoma.
[So] Source:J Cutan Pathol;45(4):296-298, 2018 Apr.
[Is] ISSN:1600-0560
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Cutaneous intravascular CD30+ pseudolymphoma is an uncommon incidental finding that may mimic intravascular or angiotropic lymphoma. We describe a 78-year-old female with a traumatized regressing keratoacanthoma on her left cheek. A shave biopsy revealed intravascular staining of atypical lymphocytes positive for CD45, CD3 and CD30. Clinical exam revealed no other evidence of lymphoma, the patient denied constitutional symptoms, and routine blood work was normal. The patient is healthy and doing well 28 months after her first visit. CD30+ pseudolymphoma should be distinguished from malignant intravascular lymphoproliferative disorders.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1801
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:In-Process
[do] DOI:10.1111/cup.13111

  2 / 1949 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Clinical Trials Registry
Full text

[PMID]: 29477665
[Au] Autor:Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D; BRIM8 Investigators
[Ad] Address:Division of Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. Electronic address: mmaiocro@gmail.com.
[Ti] Title:Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
[So] Source:Lancet Oncol;, 2018 Feb 21.
[Is] ISSN:1474-5488
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAF mutation-positive melanoma. METHODS: BRIM8 was a phase 3, international, double-blind, randomised, placebo-controlled study that enrolled 498 adults (aged ≥18 years) with histologically confirmed stage IIC-IIIA-IIIB (cohort 1) or stage IIIC (cohort 2) BRAF mutation-positive melanoma that was fully resected. Patients were randomly assigned (1:1) by an interactive voice or web response system to receive twice-daily adjuvant oral vemurafenib 960 mg tablets or matching placebo for 52 weeks (13 × 28-day cycles). Randomisation was done by permuted blocks (block size 6) and was stratified by pathological stage and region in cohort 1 and by region in cohort 2. The investigators, patients, and sponsor were masked to treatment assignment. The primary endpoint was disease-free survival in the intention-to-treat population, evaluated separately in each cohort. Hierarchical analysis of cohort 2 before cohort 1 was prespecified. This trial is registered with ClinicalTrials.gov, number NCT01667419. FINDINGS: The study enrolled 184 patients in cohort 2 (93 were assigned to vemurafenib and 91 to placebo) and 314 patients in cohort 1 (157 were assigned to vemurafenib and 157 to placebo). At the time of data cutoff (April 17, 2017), median study follow-up was 33·5 months (IQR 25·9-41·6) in cohort 2 and 30·8 months (25·5-40·7) in cohort 1. In cohort 2 (patients with stage IIIC disease), median disease-free survival was 23·1 months (95% CI 18·6-26·5) in the vemurafenib group versus 15·4 months (11·1-35·9) in the placebo group (hazard ratio [HR] 0·80, 95% CI 0·54-1·18; log-rank p=0·026). In cohort 1 (patients with stage IIC-IIIA-IIIB disease) median disease-free survival was not reached (95% CI not estimable) in the vemurafenib group versus 36·9 months (21·4-not estimable) in the placebo group (HR 0·54 [95% CI 0·37-0·78]; log-rank p=0·0010); however, the result was not significant because of the prespecified hierarchical prerequisite for the primary disease-free survival analysis of cohort 2 to show a significant disease-free survival benefit. Grade 3-4 adverse events occurred in 141 (57%) of 247 patients in the vemurafenib group and 37 (15%) of 247 patients in the placebo group. The most common grade 3-4 adverse events in the vemurafenib group were keratoacanthoma (24 [10%] of 247 patients), arthralgia (17 [7%]), squamous cell carcinoma (17 [7%]), rash (14 [6%]), and elevated alanine aminotransferase (14 [6%]), although all keratoacanthoma events and most squamous cell carcinoma events were by default graded as grade 3. In the placebo group, grade 3-4 adverse events did not exceed 2% for any of the reported terms. Serious adverse events were reported in 40 (16%) of 247 patients in the vemurafenib group and 25 (10%) of 247 patients in the placebo group. The most common serious adverse event was basal cell carcinoma, which was reported in eight (3%) patients in each group. One patient in the vemurafenib group of cohort 2 died 2 months after admission to hospital for grade 3 hypertension; however, this death was not considered to be related to the study drug. INTERPRETATION: The primary endpoint of disease-free survival was not met in cohort 2, and therefore the analysis of cohort 1 showing a numerical benefit in disease-free survival with vemurafenib versus placebo in patients with resected stage IIC-IIIA-IIIB BRAF mutation-positive melanoma must be considered exploratory only. 1 year of adjuvant vemurafenib was well tolerated, but might not be an optimal treatment regimen in this patient population. FUNDING: F Hoffman-La Roche Ltd.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Cl] Clinical Trial:ClinicalTrial
[St] Status:Publisher

  3 / 1949 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29478287
[Au] Autor:Gambichler T; Rüddel I; Hessam S; Bechara FG; Stockfleth E; Schmitz L
[Ad] Address:Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Germany.
[Ti] Title:Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery.
[So] Source:J Eur Acad Dermatol Venereol;, 2018 Feb 25.
[Is] ISSN:1468-3083
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Koebnerized non-melanoma skin cancer following skin trauma represents a rare and obscure event. OBJECTIVES: To study molecularpathological parameters in koebnerized squamous cell carcinomas (K-SCCs) occurring after complete tumour removal. METHODS: We assessed two patients with multiple sclerosis who were on treatment with dimethylfumarate (DMF) preceded by long-term azathioprine therapy. Both patients rapidly developed several K-SCCs following histopathologically proven complete excision of cutaneous SCCs. We performed immunohistochemistry for p53, p16, Ki-67, TET-2, IDH-2, 5-hmc, and 5-mc. PCR was carried out for the detection of human papilloma viruses. Mutation analysis was performed for BRAF, K-RAS, and EGFR. RESULTS: All lesions investigated were negative for HPV DNA. Mutations were not detected. Healthy appearing skin of both patients showed relatively high Ki-67, p16, and p53 expression which was comparable to the expression observed in primary SCCs as well as K-SCCs. Protein expression of Ki-67, p16, and mutant p53 was barely detected in the specimens of the healthy controls. A decreased protein expression of TET-2 enzyme was seen in all tumours and healthy appearing skin when compared to the skin of healthy controls. CONCLUSIONS: We observed two patients with K-SCCs developing under DMF treatment. In healthy appearing skin of patients with K-SCCs, wound healing processes, including induction of proliferation and growth factor release, might promote the growth of pre-neoplastic keratinocytes and cancer formation on the basis of pre-existing altered epigenetic pathways and cell cycle dysregulation. Although fumarates can reduce TET-2 expression, the role of DMF intake in the development of K-SCCs remains unclear. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180225
[Lr] Last revision date:180225
[St] Status:Publisher
[do] DOI:10.1111/jdv.14887

  4 / 1949 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29278695
[Au] Autor:Li J; Morinello E; Larsen T; Frost D; Caro I; Gould S; Wong L; Hendricks A; Dybdal N; Dambach D; Schutten M
[Ad] Address:Safety Assessment, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
[Ti] Title:Carcinogenicity assessment of the Hedgehog pathway inhibitor, vismodegib in Tg.rasH2 mice and Sprague-Dawley rats.
[So] Source:Regul Toxicol Pharmacol;92:382-389, 2018 Feb.
[Is] ISSN:1096-0295
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Vismodegib (also known as GDC-0449) is a novel small molecule inhibitor of the Hedgehog (Hh) signaling pathway currently approved for the treatment of metastatic or locally advanced basal cell carcinoma (BCC) in humans. Its tumorigenic potential was assessed in dedicated carcinogenicity studies in rasH2 transgenic (Tg.rasH2) mice and Sprague Dawley (SD) rats. Tumorigenicity potential of vismodegib was identified in rats only and was limited to benign hair follicle tumors, including pilomatricomas and keratoacanthomas at exposures of ≥0.1-fold and ≥0.6-fold, respectively, of the steady-state exposure (AUC ) of the recommended human dose. No malignant tumors were identified in either species. Overall, the totality of pharmacology and nonclinical safety data (lack of genotoxicity, in vitro secondary pharmacological binding, and immunoregulatory effects, and limited effects on the endocrine system) suggests that the development of the benign hair follicle tumors may be related to pharmacologically-mediated disruption of hair follicle morphogenesis, although the exact mechanism of tumorigenesis is unclear. Hair follicle tumors have not been reported in vismodegib-treated patients. The relevance of this finding in rats to patients is uncertain.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180206
[Lr] Last revision date:180206
[St] Status:In-Process

  5 / 1949 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29263542
[Au] Autor:Das A; Podder I; Bhattacharya S; Gharami RC; Jash PK
[Ad] Address:Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India.
[Ti] Title:Calcified Keratoacanthoma with Tumoral Calcinosis in a 10-year-old Boy: A mere Co-incidence?
[So] Source:Indian J Dermatol;62(6):654-657, 2017 Nov-Dec.
[Is] ISSN:1998-3611
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Keratoacanthoma (KA) is a rapidly evolving benign cutaneous tumor, occurring in elderly individuals with a tendency towards spontaneous regression and histopathologic similarity to squamous cell carcinoma. Tumoral calcinosis is an uncommon condition, associated with the deposition of painless calcific masses. The occurrence of these two conditions in the same patient is a rarity itself, whereas deposition of calcium within the KA lesion in our 13-year-old patient makes it even more intriguing. Such an association has been seldom reported in the literature, and this prompted the current report.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 171224
[Lr] Last revision date:171224
[St] Status:In-Data-Review
[do] DOI:10.4103/ijd.IJD_304_16

  6 / 1949 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29266386
[Au] Autor:Kogame T; Ohe S; Yamazaki F; Okamoto H; Kiyohara T
[Ad] Address:Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
[Ti] Title:Extraocular sebaceous carcinoma accompanied by invasive squamous cell carcinoma: The first case report and consideration of histogenesis.
[So] Source:J Dermatol;, 2017 Dec 21.
[Is] ISSN:1346-8138
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:A 61-year-old man presented with a dome-shaped nodule, 1.2 cm in size, with a central crater covered by keratinous material near the left lateral malleolus. Histological findings demonstrated a basophilic circular cone in the center, surrounded and sharply demarcated by a broad eosinophilic area. The central conical mass was composed mainly of atypical basaloid cells intermingled with scattered atypical sebaceous cells with scalloped nuclei and microvesicular cytoplasms, suggesting sebaceous carcinoma. The peripheral area consisted of atypical keratinizing squamoid cells without sebaceous cells, suggesting invasive squamous cell carcinoma. Atypical sebaceous cells were positive for adipophilin. Atypical basaloid cells were positive for 34ßE12 and CAM5.2. Peripheral squamoid cells were positive for 34ßB4 and 34ßE12 throughout, and were positive for LHP1 in the superficial layer. We herein describe the first case of extraocular sebaceous carcinoma accompanied by invasive squamous cell carcinoma, which might have arisen from biphasic differentiation of cancer stem cells.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 171221
[Lr] Last revision date:171221
[St] Status:Publisher
[do] DOI:10.1111/1346-8138.14196

  7 / 1949 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29235666
[Au] Autor:Fukumoto T; Takai T; Sakaguchi M; Oka M; Nishigori C
[Ad] Address:Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.
[Ti] Title:Complete regression of crateriform verruca after partial biopsy: Another type of epithelial crateriform tumor or a subtype of keratoacanthoma?
[So] Source:J Dermatol;, 2017 Dec 13.
[Is] ISSN:1346-8138
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1712
[Cu] Class update date: 171213
[Lr] Last revision date:171213
[St] Status:Publisher
[do] DOI:10.1111/1346-8138.14186

  8 / 1949 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29126557
[Au] Autor:Kluger N; Douvin D; Dupuis-Fourdan F; Doumecq-Lacoste JM; Descamps V
[Ad] Address:University of Helsinki, Helsinki university central hospital, departments of dermatology, allergology and venereology, 00029 Helsinki, Finlande; Consultation « tatouage ¼, service de dermatologie, hôpital Bichat - Claude-Bernard, hôpitaux universitaires Paris-Nord-Val-de-Seine, 46, rue Henri-Huchard
[Ti] Title:Kératoacanthomes sur tatouages récents : deux cas. [Keratoacanthomas on recent tattoos: Two cases].
[So] Source:Ann Dermatol Venereol;144(12):776-783, 2017 Dec.
[Is] ISSN:0151-9638
[Cp] Country of publication:France
[La] Language:fre
[Ab] Abstract:BACKGROUND: Increasing numbers of reports of rapidly arising, isolated or eruptive keratoacanthomas (KA) and squamous cell carcinomas (CSC) on the red part of tattoos tend to suggest a non-fortuitous link with the procedure. We report herein two different presentations of KAs on tattoos: one patient with multiple eruptive KAs on sun-exposed areas of a recent red tattoo and another with a solitary lesion on a recent tattoo. We discuss the issues related to the distinction between KAs and CSCs in this particular context. PATIENTS AND METHODS: Case No. 1: A 55-year-old heavily tattooed man presented multiple round keratotic verrucous-like lesions restricted to a red tattoo. The tattoo had been performed by a professional tattooist in summer 2016, a week before the onset of the symptoms. The patient did not protect a part of his tattoo from sun-exposure during the healing phase and lesions developed only on the sun-exposed tattooed parts. In January 2017, he consulted with about ten lesions. The histologic study by shaving of a lesion militated in favor of a CSC, KA type. The physical examination was unremarkable. He had no previous history of skin cancer. Two weeks later, most of the lesions regressed spontaneously. Based on the clinical history and progression of the lesions, a diagnosis was made of eruptive KA on a red tattoo. Residual lesions were treated by cryotherapy or excision. Case No. 2: A 72-year-old woman developed a 1-cm painful dome-shaped nodule with a central crust three weeks after tattooing. Full excision confirmed the diagnosis of KA. DISCUSSION: To date, we have found 31 case reports and series (17 men, median age: 50.5 years) of KA and CSC on tattoos. Lesions usually develop rapidly after completion of the tattoo, after between one week and several months. Exceptional cases have been described in old tattoos. Red tattoo ink is most commonly the culprit. The main difficulty lies in distinguishing between KA and CSC. Nowadays pathologists agree that a KA should be considered as a variant of CSC. Eruptive forms of KA present a peculiar situation. They may sometimes be inherited, and KA on recent traumatized areas or drug-induced have been described. Like other authors, we believe that cases of CSC on red tattoos belong rather to the KA type. The physiopathogenesis of tattoo-associated eruptive KA and CSC is not clearly understood, but could be multifactorial, involving: the trauma induced by tattooing, local inflammatory reaction, a component of the red ink, external factors such UV exposure, and a possible genetic predisposition. Rapidly arising KA and eruptive KA on top of recent (red) tattoos are not fortuitous. The lesions should be excised and the patient monitored. Additional studies on tumor specimens are warranted to identify the possible causative agents in tattoo ink that may be responsible for such reactions.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171124
[Lr] Last revision date:171124
[St] Status:In-Process

  9 / 1949 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29124377
[Au] Autor:Paprottka FJ; Krezdorn N; Narwan M; Turk M; Sorg H; Noah EM; Hebebrand D
[Ad] Address:Department of Plastic, Aesthetic, Reconstructive and Hand Surgery, AGAPLESION Diakonieklinikum Rotenburg, Elise-Averdieck-Straße 17, 27356, Rotenburg (Wümme), Germany. felix.paprottka@me.com.
[Ti] Title:Trendy Tattoos-Maybe a Serious Health Risk?
[So] Source:Aesthetic Plast Surg;, 2017 Nov 09.
[Is] ISSN:1432-5241
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The literature reports many cases of cutaneous malignancy in the setting of skin tattoos. In this study, we review the reported incidence of and risk factors for tattoo-associated skin cancer. METHODS: A PubMed literature review was performed for all cases of tattoo-associated skin cancer, including squamous cell carcinoma, basal cell carcinoma, malignant melanoma, keratoacanthoma, and other rare skin malignancies (source: PubMed/until June 2017). RESULTS: The authors identified 51 publications and 63 total cases of tattoo-associated skin cancer. We also report on a single new case of tattoo-associated skin cancer observed at one of our co-authors' institutions. Among these 64 total cases, 58% were associated with black and blue inks and 34% were associated with red ink. CONCLUSIONS: Overall, while the strength of association remains unclear, the literature reports many cases of tattoo-associated skin cancer. Among these cases, black, blue, and red inks were particularly worrisome for their carcinogenic potential. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171110
[Lr] Last revision date:171110
[St] Status:Publisher
[do] DOI:10.1007/s00266-017-1002-0

  10 / 1949 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29084636
[Au] Autor:Russo I; Zorzetto L; Frigo AC; Chiarion Sileni V; Alaibac M
[Ad] Address:Unit of Dermatology, University of Padua, Via Gallucci 4, 35128 Padova, Italy.
[Ti] Title:A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
[So] Source:Eur J Dermatol;27(5):482-486, 2017 Oct 01.
[Is] ISSN:1952-4013
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:Patients with advanced melanoma have a poor prognosis. Since the discovery of BRAF mutations in cutaneous melanoma, new pharmacological agents have been developed to inhibit this target. Although the survival of patients with advanced melanoma has improved with BRAF inhibitors, the emergence of drug resistance and the high incidence of cutaneous side effects represent important limitations. The aim of our study was to compare the incidence of cutaneous side effects between BRAF inhibitor monotherapy and BRAF and MEK inhibitor combination therapy in our cohort of patients. This study was a longitudinal prospective observational study. The study population comprised 83 patients with advanced cutaneous melanoma presenting with BRAF V600 mutation. The inclusion criteria included: age above 18 years, metastatic cutaneous melanoma or melanoma with high risk of metastasis, the presence of BRAF V600 mutation, and treatment with BRAF inhibitors or a combination of BRAF and MEK inhibitors. The majority of patients developed skin toxicity during treatment. The most common cutaneous side effects were localized hyperkeratosis and verrucous keratosis. Other cutaneous side effects observed were photosensitivity, squamous cell carcinoma, and keratoacanthoma. Our results indicate that cutaneous side effects are generally observed during BRAF inhibitor monotherapy and are significantly different from those observed in patients treated with combination therapy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171031
[Lr] Last revision date:171031
[St] Status:In-Process
[do] DOI:10.1684/ejd.2017.3069


page 1 of 195 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information